Mechanism-led. Evidence-ranked. No hype, no dosing advice, just the research, written for people who actually want to understand it.
The FDA's advisory committee recommended six of seven peptides for inclusion on the 503A Bulks List. overruling its own scientists on every one. Here's the compound-by-compound breakdown, what the vote actually means, and what hasn't changed.
The advisory committee overruled FDA staff on BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon. Emideltide (DSIP) failed by one vote. Compound-by-compound: what was voted, what FDA objected to, and what happens next.
The background piece. What the PCAC is, what the compounding pathway means, and why restricting the safest pathway pushes people to less regulated ones. Now updated with the July vote outcome.
The most-searched peptide stack in biohacking. BPC-157 for tissue repair signaling. TB-500 for systemic recovery. Here is what the research actually says about using them together.
Three generations of incretin therapy. One receptor, two receptors, three receptors. The weight loss numbers keep climbing. A plain-English breakdown of what each adds and what the trials show.
RUO is a regulatory lane, not a quality grade. A high-purity research peptide and a compounded pharmacy peptide can come from the same synthesis run. The confusion has real consequences.
Fentanyl has been found in peptide products. Not a headline designed to scare you. A documented fact about where the real risk in this market lives. Here is the framework for thinking about it.
Seven compounds, one committee, a lot of noise. Compound-by-compound breakdown of the July 2026 PCAC review and what actually changed in practice for each one.
Every regulatory framework for this space is built around one type of person. It consistently ignores the other, the self-directed optimizer. Here is why that gap produces worse outcomes for everyone.
Amino acids, peptide bonds, half-life, bioavailability, the vocabulary you need to read peptide research without getting lost. The foundation everything else builds on.
Most peptide research used male subjects. Here is what the data shows specifically for women, from PT-141 for desire to GHK-Cu for skin to GLP-1 agents for metabolic health.
The skincare industry sells peptides hard. Here is what the research actually supports, from GHK-Cu's collagen data to Matrixyl's clinical trials to where the evidence gets thin.